NCT00145314View on ClinicalTrials.gov

FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

571

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

August 31, 2010

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

FLOX (5-fluorouracil/folinic acid/oxaliplatin)

FLOX every 2nd week

DRUG

FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab

FLOX every 2nd week Cetuximab weekly

DRUG

FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab

"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly."

Trial Locations (1)

NO-0407

The Nordic Colorectal Cancer Biomodulation Group, Oslo

All Listed Sponsors
lead

The Nordic Colorectal Cancer Biomodulation Group

OTHER

NCT00145314 - FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer | Biotech Hunter | Biotech Hunter